NICE Recommends Pfizer’s Breast Cancer Treatment

December 29, 2017

The National Institute for Health and Care Excellence (NICE) recommended Pfizer’s palbociclib for treatment of locally advanced or metastatic breast cancer.

NICE made the recommendation based on a review of a Pfizer submission concluding the drug was clinically effective based on a 666-patient clinical trial and a smaller 165-patient open-label study.

The drug is only recommended if Pfizer provides it with the discount agreed in the patient access scheme, the institute said.

View today's stories